Contraindications of<unk>  include pregnancy, known osteoporosis, severe hepatic impairment, and concomitant use with strong organic anion-transporting polypeptide (OATP) 1B1 inhibitors such as ciclosporin and gemfibrozil.<unk>  may increase the risk of miscarriage in early pregnancy. Women should avoid pregnancy while taking<unk> , for instance by using birth control, and should discontinue the medication if they become or wish to become pregnant.<unk>  should not be used in women with osteoporosis because it may increase the risk of further bone loss. Severe hepatic impairment is associated with 7-fold increased exposure to<unk> , which may increase the risk of bone loss. In women with moderate hepatic impairment, which is associated with 3-fold increased exposure to<unk> , the medication at 200 mg twice per day should not be used, while 150 mg once per day should be used for no more than 6 months. OATP1B1 inhibitors are likely to greatly increase exposure to<unk>  similarly to moderate to severe hepatic impairment. Combined birth control is not contraindicated with<unk> , but because of the estrogen component, is expected to decrease the effectiveness of<unk>  in the treatment of endometriosis, and hence is not recommended. Other forms of birth control, such as non-hormonal birth control, can be used instead.<unk>  is not contraindicated in women who are breastfeeding, but it is unknown whether the medication is excreted in breast milk or if it has adverse effects on milk production or the breastfed child. The use of<unk>  in women who are breastfeeding should be considered carefully, weighing both benefits and risks.
Elagolix
Lifitegrast
Naloxegol
Relugolix
Naldecon
Syclix
Crofelemer
Abarelix